Cover Image
市場調查報告書

移行性上皮細胞癌(泌尿道上皮細胞癌):開發中產品分析

Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 213070
出版日期 內容資訊 英文 320 Pages
訂單完成後即時交付
價格
Back to Top
移行性上皮細胞癌(泌尿道上皮細胞癌):開發中產品分析 Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H2 2015
出版日期: 2015年09月16日 內容資訊: 英文 320 Pages
簡介

移行性上皮細胞癌(泌尿道上皮細胞癌)是泌尿系統典型癌症的一種。腫瘤產生於從腎盞到尿道口、尿道內側的移行上皮(泌尿道上皮)細胞上。症狀有血尿,排尿時疼痛或加熱感(沒有肉眼可見的尿道感染或排尿習慣沒有變化下)。危險因素包含年齡,抽煙,性別,家族病史等。

本報告提供移行性上皮細胞癌(泌尿道上皮細胞癌)的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等相關的系統性資訊。

目錄

簡介

移行性上皮細胞癌(泌尿道上皮細胞癌)概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

開發中的產品:各企業

治療藥的開發企業

  • Altor BioScience Corporation
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Boston Biomedical, Inc.
  • 第一三共
  • Dendreon Corporation
  • Eli Lilly and Company
  • Exelixis, Inc.
  • GlaxoSmithKline plc
  • Innate Therapeutics Limited
  • Merck & Co., Inc.
  • Merck KGaA
  • Mirati Therapeutics Inc.
  • Novartis AG
  • Sanofi
  • 大日本住友製藥
  • Teva Pharmaceutical Industries Limited
  • TRACON Pharmaceuticals, Inc.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AGS-15E
  • ALT-801
  • amrubicin hydrochloride
  • ASG-15ME
  • AZD-4547
  • BBI-503
  • buparlisib hydrochloride
  • cabazitaxel
  • cabozantinib s-malate
  • CEP-11981
  • dovitinib lactate
  • enfortumab vedotin
  • lapuleucel-t
  • MIS-416
  • mocetinostat
  • MSB-0010718C
  • pembrolizumab
  • ramucirumab
  • SAR-408701
  • SNX-5422
  • tigatuzumab
  • trametinib dimethyl sulfoxide
  • TRC-105

開發中產品的最新趨勢

開發暫停中的計劃

開發中止的計劃

產品開發的里程碑

  • 熱門新聞和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7098IDB

Summary

Global Markets Direct's, 'Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H2 2015', provides an overview of the Transitional Cell Cancer (Urothelial Cell Cancer)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Transitional Cell Cancer (Urothelial Cell Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Cancer (Urothelial Cell Cancer) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Transitional Cell Cancer (Urothelial Cell Cancer)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Transitional Cell Cancer (Urothelial Cell Cancer) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Transitional Cell Cancer (Urothelial Cell Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Transitional Cell Cancer (Urothelial Cell Cancer) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Transitional Cell Cancer (Urothelial Cell Cancer)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Transitional Cell Cancer (Urothelial Cell Cancer) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Transitional Cell Cancer (Urothelial Cell Cancer) Overview
  • Therapeutics Development
    • Pipeline Products for Transitional Cell Cancer (Urothelial Cell Cancer) - Overview
    • Pipeline Products for Transitional Cell Cancer (Urothelial Cell Cancer) - Comparative Analysis
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Therapeutics under Development by Companies
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Products under Development by Companies
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Companies Involved in Therapeutics Development
    • Altor BioScience Corporation
    • Amgen Inc.
    • Astellas Pharma Inc.
    • AstraZeneca Plc
    • ATLAB Pharma SAS
    • Bayer AG
    • BIND Therapeutics, Inc.
    • Boehringer Ingelheim GmbH
    • Boston Biomedical, Inc.
    • Celgene Corporation
    • Corcept Therapeutics Incorporated
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • Exelixis, Inc.
    • Incyte Corporation
    • Innate Immunotherapeutics Limited
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Merck KGaA
    • Millennium Pharmaceuticals, Inc.
    • Mirati Therapeutics Inc.
    • Novartis AG
    • Ono Pharmaceutical Co., Ltd.
    • Pfizer Inc.
    • PsiOxus Therapeutics Limited
    • Sanofi
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Teva Pharmaceutical Industries Limited
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ACP-196 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AdIL-24 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • afatinib dimaleate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALT-801 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AMG-228 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • amrubicin hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASG-15ME - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATL-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • avelumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AZD-4547 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • B-701 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BBI-503 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • buparlisib hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cabazitaxel - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cabozantinib s-malate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CEP-11981 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • docetaxel - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • enadenotucirev - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • enfortumab vedotin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • epacadostat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eribulin mesylate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • everolimus - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • gedatolisib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • icrucumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INCB-54828 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ixazomib citrate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JNJ-42756493 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lenalidomide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lenvatinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mifepristone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MIS-416 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mitomycin SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mocetinostat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nintedanib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nivolumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • palbociclib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pembrolizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ramucirumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • regorafenib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SAR-408701 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sunitinib malate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • trametinib dimethyl sulfoxide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vandetanib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Recent Pipeline Updates
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Dormant Projects
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Discontinued Products
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Product Development Milestones
    • Featured News & Press Releases
      • May 30, 2015: Mirati Therapeutics Provided Updates on Mocetinostat at 2015 ASCO Annual Meeting
      • May 13, 2015: Mirati Therapeutics to Provide Updates on Mocetinostat at 2015 ASCO Annual Meeting
      • May 07, 2013: Exelixis To Feature Nine Presentations On Cabozantinib At 2013 ASCO Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Transitional Cell Cancer (Urothelial Cell Cancer), H2 2015
  • Number of Products under Development for Transitional Cell Cancer (Urothelial Cell Cancer) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Altor BioScience Corporation, H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Amgen Inc., H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Astellas Pharma Inc., H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by AstraZeneca Plc, H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by ATLAB Pharma SAS, H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Bayer AG, H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by BIND Therapeutics, Inc., H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Boehringer Ingelheim GmbH, H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Boston Biomedical, Inc., H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Celgene Corporation, H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Corcept Therapeutics Incorporated, H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Eisai Co., Ltd., H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Eli Lilly and Company, H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Exelixis, Inc., H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Incyte Corporation, H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Innate Immunotherapeutics Limited, H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Johnson & Johnson, H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Merck & Co., Inc., H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Merck KGaA, H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Mirati Therapeutics Inc., H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Novartis AG, H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Pfizer Inc., H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by PsiOxus Therapeutics Limited, H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Sanofi, H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics - Recent Pipeline Updates, H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Dormant Projects, H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Dormant Projects (Contd..1), H2 2015
  • Transitional Cell Cancer (Urothelial Cell Cancer) - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Transitional Cell Cancer (Urothelial Cell Cancer), H2 2015
  • Number of Products under Development for Transitional Cell Cancer (Urothelial Cell Cancer) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top